La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Pulse Biosciences Gestione

Gestione criteri di controllo 2/4

Pulse Biosciences' Il CEO è Burke Barrett, nominato in May2024, ha un mandato di meno di un anno. possiede direttamente 0.02% delle azioni della società, per un valore di $ 233.82K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.4 anni e 6.8 anni.

Informazioni chiave

Burke Barrett

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	0.02%
Durata media del management	2.5yrs
Durata media del Consiglio di amministrazione	6.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

What Percentage Of Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares Do Insiders Own?

Jan 20

Pulse Biosciences' CellFX System U.S. application moves forward for general dermatology indication

Jan 12

We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate

Dec 16

AMMINISTRATORE DELEGATO

Burke Barrett (60 yo)

less than a year

Mandato

Mr. Burke T. Barrett is President & CEO of Pulse Biosciences, Inc. from May 14, 2024 and also serves as its Director since May 2024. Mr. Barrett served as President, Secretary and Director of CardioFocus,...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Robert Duggan	Executive Co-Chairman	6.8yrs	US$257.41k	69.46% $ 732.5m
Darrin Uecker	CTO & Director	2yrs	US$5.39m	0.25% $ 2.6m
Mitchell Levinson	Chief Strategy Officer	3.1yrs	US$1.69m	0.22% $ 2.3m
Kevin Danahy	Chief Commercial Officer	less than a year	US$5.86m	0.060% $ 628.6k
Burke Barrett	President	less than a year	Nessun dato	0.020% $ 209.4k
Edison Manuel	Vice President of Operations	7.4yrs	Nessun dato	Nessun dato
Richard Nuccitelli	Chief Science Officer	9.8yrs	Nessun dato	Nessun dato
Kenneth B. Stratton	General Counsel & Corporate Secretary	3.3yrs	Nessun dato	Nessun dato
Patty Perla	Vice President of Human Resources	4.7yrs	Nessun dato	Nessun dato
David Danitz	Senior Vice President of Engineering	3yrs	Nessun dato	Nessun dato
Gansevoort Dunnington	Chief Medical Officer	1.3yrs	Nessun dato	Nessun dato
Niv Ad	Chief Science Officer of Cardiac Surgery	less than a year	Nessun dato	Nessun dato

2.5yrs

Durata media

59yo

Età media

Gestione esperta: Il team dirigenziale di PLSE è considerato esperto (durata media dell'incarico 2.4 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Robert Duggan	Executive Co-Chairman	6.8yrs	US$257.41k	69.46% $ 732.5m
Darrin Uecker	CTO & Director	9yrs	US$5.39m	0.25% $ 2.6m
Burke Barrett	President	less than a year	Nessun dato	0.020% $ 209.4k
Richard van den Broek	Independent Director	4.1yrs	US$208.89k	0% $ 0
Paul LaViolette	Independent Co-Chairman of the Board	less than a year	Nessun dato	Nessun dato
Mahkam Zanganeh	Independent Director	7.6yrs	US$173.00k	1.33% $ 14.0m
Manmeet Soni	Lead Independent Director	6.8yrs	US$180.07k	0% $ 0

6.8yrs

Durata media

58yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di PLSE sono considerati esperti (durata media dell'incarico 6.8 anni).

Pulse Biosciences Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

Shelley D. Spray Does Not Stand for Reelection from the Board of Pulse Biosciences, Inc

President & CEO recently bought US$86k worth of stock

Pulse Biosciences, Inc Announces CEO Changes

Pulse Biosciences, Inc., Annual General Meeting, Jun 06, 2024

Executive Chairman exercised options to buy US$382k worth of stock.

Recent updates

Pulse Biosciences, Inc. announced delayed 10-Q filing

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System

Pulse Biosciences, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Pulse Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $60 million.

Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation

Pulse Biosciences, Inc.(NasdaqCM:PLSE) dropped from Russell Small Cap Comp Value Index

Shelley D. Spray Does Not Stand for Reelection from the Board of Pulse Biosciences, Inc

President & CEO recently bought US$86k worth of stock

Pulse Biosciences Stock: Signs Of Life Following Q1 Update

Pulse Biosciences, Inc Announces CEO Changes

We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate

Pulse Biosciences, Inc. Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System

New major risk - Financial position

Pulse Biosciences, Inc. to Report Q1, 2024 Results on May 07, 2024

Pulse Biosciences, Inc., Annual General Meeting, Jun 06, 2024

Pulse Biosciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System

Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp

We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth

Pulse Biosciences, Inc. Announces First-In-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation Cardiac Catheter

Executive Chairman exercised options to buy US$382k worth of stock.

Executive Chairman recently bought US$1.1m worth of stock

Pulse Biosciences, Inc. Announces Filing of Premarket Notification 510(k) to U.S. Food and Drug Administration for its Novel CellFX nsPFA Percutaneous Electrode

Chief Strategy Officer recently bought US$105k worth of stock

Executive Chairman exercised options to buy US$68k worth of stock.

Pulse Biosciences, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Pulse Biosciences, Inc. Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery

We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth

New major risk - Revenue and earnings growth

Pulse Biosciences, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Executive Chairman exercised options to buy US$881k worth of stock.

Executive Chairman exercised options to buy US$36m worth of stock.

Independent Director exercised options to buy US$543k worth of stock.

Pulse Biosciences, Inc. Appoints f Gansevoort 'Gan' Dunnington, M.D. as Its Chief Medical Officer

Pulse Biosciences (NASDAQ:PLSE) Has Debt But No Earnings; Should You Worry?

Pulse Biosciences, Inc. Announces Resignation of Sandra Gardiner as Chief Financial Officer

Pulse Biosciences, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Chief Strategy Officer & Director recently bought US$70k worth of stock

Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions

Pulse Biosciences, Inc. Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia

Pulse Biosciences, Inc. Announces Executive Changes

Pulse Biosciences appoints Kevin Danahy as CEO; Darrin Uecker to serve as CTO

Consensus revenue estimates fall by 31%

Pulse Biosciences, Inc. Receives FDA 510(K) Clearance of Expanded Energy Settings for Use with the CellFX System

Pulse Biosciences, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Pulse Biosciences, Inc.(NasdaqCM:PLSE) dropped from Russell 2000 Dynamic Index

Pulse Biosciences, Inc. has completed a Composite Units Offering in the amount of $15 million.

Consensus forecasts updated

Price target decreased to US$11.17

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Pulse Biosciences, Inc

Consensus forecasts updated

Companies Like Pulse Biosciences (NASDAQ:PLSE) Could Be Quite Risky

Pulse Biosciences, Inc., Annual General Meeting, May 19, 2022

Pulse Biosciences, Inc. to Report Q4, 2021 Results on Mar 31, 2022

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Pulse Biosciences, Inc

Pulse Biosciences Announces the Appointment of Kevin Danahy as Chief Commercial Officer

Pulse Biosciences, Inc Provides an Update on Recent FDA 510(k) Submission

Price target decreased to US$35.33

Price target decreased to US$35.33

Pulse Biosciences, Inc. Provides Revenue Guidance for the Fourth Quarter 2021

Forecast to breakeven in 2024

Is Pulse Biosciences (NASDAQ:PLSE) Using Debt In A Risky Way?

Consensus forecasts updated

Price target decreased to US$37.95

Independent Chairman of the Board recently bought US$50m worth of stock

Pulse Biosciences, Inc. Announces First CellFX Procedure Performed in Canada

Pulse Biosciences Announces Health Canada Approval for CellFX® System

Pulse Biosciences gets Health Canada approval for CellFX System